Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia; a Multicenter, Observational Study

NCT05282108 is registered in ClinicalTrials.gov with Hikma Pharmaceuticals LLC as lead sponsor.

NCT NCT05282108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05282108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia; a Multicenter, Observational Study
Lead sponsor
Hikma Pharmaceuticals LLC
Phase
Observational
Overall status
Recruiting
Start date
July 20, 2022
Completion date
November 30, 2026
Enrollment
240 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia